ations of the disorder; 7) reduces the risk that the individual will develop the disorder; and 8) reduces the amount of a therapeutic agent, other than a TLR agonist, that needs to be administered. [0050] In some embodiments, an ???effective amount??? of a TLR agonist is an amount that results in a reduction of at least one pathological parameter or symptom associated with interstitial lung diseas